| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CPR |
| Uniprot No | P16435 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-671aa |
| 氨基酸序列 | INMGDSHVDTSSTVSEAVAEEVSLFSMTDMILFSLIVGLLTYWFLFRKKKEEVPEFTKIQTLTSSVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWLAVCEHFGVEATGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHLMHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPVGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVDYIKKLMTK |
| 预测分子量 | 102.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CPR(细胞色素P450还原酶)重组蛋白的3篇参考文献示例(注：文献信息为示例，非真实存在)：
---
1. **文献名称**：*Optimized Expression and Functional Characterization of Recombinant Human Cytochrome P450 Reductase in Escherichia coli*
**作者**：Shen, A. et al.
**摘要**：研究通过优化大肠杆菌表达系统(如温度、诱导剂浓度)，提高重组人源CPR的可溶性表达及活性，证实其在体外支持细胞色素P450酶催化反应的能力。
2. **文献名称**：*Structural Insights into Conformational Dynamics of CPR Revealed by Cryo-EM*
**作者**：Wang, L. et al.
**摘要**：利用冷冻电镜技术解析了重组CPR的构象变化，揭示了其从“闭合”到“开放”状态的动态转换机制，阐明了电子传递至细胞色素P450的结构基础。
3. **文献名称**：*Mechanistic Interplay between CPR and CYP3A4 in Drug Metabolism*
**作者**：Hanna, I. & Waterman, M.
**摘要**：通过重组CPR与CYP3A4的共表达实验，证明两者相互作用的关键结构域，并探讨了CPR活性对药物代谢动力学的影响。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词(如“recombinant cytochrome P450 reductase expression”)。
Cytochrome P450 reductase (CPR), a critical electron-transfer partner in the cytochrome P450 (CYP) enzyme system, plays a central role in oxidative metabolism across biological systems. This membrane-bound flavoprotein facilitates electron transfer from NADPH to CYP enzymes, enabling their catalytic functions in detoxification, steroidogenesis, and drug metabolism. Structurally, CPR contains distinct FMN, FAD, and NADPH-binding domains, enabling its redox activity.
Recombinant CPR proteins are engineered via heterologous expression systems (e.g., E. coli, yeast, or mammalian cells) to study structure-function relationships, optimize enzymatic activity, or develop biosensors. Their production often involves gene cloning, codon optimization, and purification strategies (e.g., affinity chromatography) to ensure proper folding and functionality. Recombinant CPR retains the ability to interact with diverse CYP isoforms, making it invaluable for in vitro drug metabolism studies, toxicity screening, and synthetic biology applications.
Research on recombinant CPR has advanced understanding of metabolic disorders, drug-drug interactions, and evolutionary adaptations in CYP systems. It also supports industrial biocatalysis for producing pharmaceuticals or bioactive compounds. Challenges include maintaining stability in soluble forms and mimicking native membrane environments. Recent efforts focus on engineering CPR variants with enhanced catalytic efficiency or altered substrate specificity, aligning with precision medicine and green chemistry goals. Overall, recombinant CPR remains a cornerstone tool for probing redox biology and refining biotechnological applications reliant on P450 systems.
(Word count: 246)
×
